In the BioHarmony Drug Report Database
Panobinostat
Farydak (panobinostat) is a small molecule pharmaceutical. Panobinostat was first approved as Farydak on 2015-02-23. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target histone deacetylase 4, histone deacetylase 1, histone deacetylase 9, histone deacetylase 2, histone deacetylase 8, histone deacetylase 6, histone deacetylase 7, and histone deacetylase 3. Farydak’s patents are valid until 2028-06-13 (FDA).
Trade Name
|
Farydak |
|---|---|
Common Name
|
panobinostat |
ChEMBL ID
|
CHEMBL483254 |
Indication
|
multiple myeloma |
Drug Class
|
Enzyme inhibitors: inhibitors of histone deacetylase |
Image (chem structure or protein)